Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.44 |
| ▸ | CNR2 | P34972 | 5/20 | 0.44 |
| ▸ | CCR3 | P51677 | 8/20 | 0.44 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21481977 | 0.94 | CNR1 (0.43) | CNR1CNR2CCR3CRHR1CRHR2 | |
| SCHEMBL21481949 | 0.92 | CNR1 (0.44) | CNR1CNR2CCR3CRHR1CRHR2 | |
| SCHEMBL22927221 | 0.92 | CNR2 (0.52) | CNR1CNR2CCR3FAAH | |
| SCHEMBL23185752 | 0.87 | CRHR1 (0.42) | CNR1CNR2CCR3CRHR1CRHR2 | |
| SCHEMBL21458154 | 0.85 | CCR3 (0.38) | CNR1CNR2CCR3CRHR1CRHR2 | |
| SCHEMBL31203518 | 0.85 | CCR3 (0.38) | CNR1CNR2CCR3CRHR1CRHR2 | |
| SCHEMBL21481956 | 0.85 | PTGER4 (0.45) | CNR1CNR2CCR3FAAHCYP2D6 | |
| SCHEMBL31203456 | 0.85 | PTGER4 (0.45) | CNR1CNR2CCR3FAAHCYP2D6 | |
| SCHEMBL21458244 | 0.85 | PTGER4 (0.45) | CNR1CNR2CCR3FAAHCYP2D6 | |
| SCHEMBL21485583 | 0.85 | CRHR1 (0.46) | CNR1CNR2CCR3CRHR1CRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968201-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | CNR1 6/4885CNR2 3/4885CCR3 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.